Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary autologous bone marrow mononuclear cell infusion for chronic coronary occlusion with ventricular dysfunction
2013-000915-26Phase 3Suspended
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Apr 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in Chronic coronary occlusion (CTO) and coronary occlusion, sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Change in ejection fraction. Started Apr 2013; status: suspended.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Chronic coronary occlusion (CTO)coronary occlusion
Beyond the preview
Go deeper on 2013-000915-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000915-26.